Nuevo Usuario

Recordar Contraseña

Revisiones en Cáncer 00111 / http://dx.doi.org/10.20960/revcancer.00111

Resumen| PDF

Revisión

Epidemiología y factores de riesgo del carcinoma hepatocelular

Ezequiel Mauro, Alejandro Forner González

Prepublicado: 2025-06-13

Logo Descargas Número de descargas: 173 Logo Visitas Número de visitas: 23 Citas Citas: 0

Compártelo:

El carcinoma hepatocelular (CHC) es una de las neoplasias malignas más comunes a nivel mundial y representa una causa significativa de mortalidad relacionada con el cáncer. La incidencia de CHC varía geográficamente. Es más alta en regiones con prevalencia elevada de infecciones crónicas por virus de la hepatitis B (VHB), como el sudeste asiático y el África subsahariana. La presencia de hepatopatía crónica avanzada, independientemente de la etiología, constituye el factor predisponente más importante para el desarrollo del CHC. Entre los factores de riesgo más importantes para el desarrollo de CHC se encuentran las infecciones crónicas por VHB y VHC, que son responsables de la mayoría de los casos a nivel mundial. Además, el consumo excesivo de alcohol y la disfunción metabólica asociada a la enfermedad hepática se han identificado como factores de riesgo en aumento. En este capítulo revisaremos los aspectos más relevantes de la epidemiología del CHC.

Palabras Clave: Carcinoma hepatocelular. Epidemiología. Factores de riesgo. Prevención.

Descargar PDF

Bibliografía
Artículos Relacionados

World Health Organization (WHO). International Agency for Research on Cancer. Fact Sheets by Population-Globocan-IARC. Disponible en: http://globocan.iarc.fr/Pages/fact sheets population.aspx

Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol 2023;20:864-84.
DOI: 10.1038/s41571-023-00825-3

Liu Y, Zheng J, Hao J, et al. Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019. Cancer Med 2022;11:1310-23.
DOI: 10.1002/cam4.4551

Cui F, Blach S, Manzengo Mingiedi C, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol Hepatol 2023;8:332-42.
DOI: 10.1016/S2468-1253(22)00386-7

Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855-9.
DOI: 10.1056/NEJM199706263362602

Chang M-H, You S-L, Chen C-J, et al. Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer. Gastroenterology 2016;0:21-6.

Rodríguez M, Buti M, Esteban R, et al. Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). Gastroenterol Hepatol 2020;43:559-87.
DOI: 10.1016/j.gastrohep.2020.03.011

Hou JL, Zhao W, Lee C, et al. Outcomes of Long-term Treatment of Chronic VHB Infection with Entecavir or Other Agents from a Randomized Trial in 24 Countries. Clin Gastroenterol Hepatol 2020;18:457-467.e21.
DOI: 10.1016/j.cgh.2019.07.010

Su T-H, Hu T-H, Chen C-Y, et al. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver International 2016;36:1755-64.
DOI: 10.1111/liv.13253

Kim JH, Sinn DH, Kang W, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology 2017;66:335-43.
DOI: 10.1002/hep.28916

Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol 2016;64:800-6.
DOI: 10.1016/j.jhep.2015.11.035

Cheuk-Fung Yip T, Lai-Hung Wong G, Wai-Sun Wong V, et al. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B. J Hepatol 2020;72:847-54.
DOI: 10.1016/j.jhep.2019.12.005

Ministerio de Sanidad, Consumo y Bienestar Social. Grupo de trabajo del estudio de prevalencia de la infección por hepatitis C en población general en España; 2017-2018. Resultados del 2.o Estudio de Seroprevalencia en España (2017-2018). Ministerio de Sanidad, Consumo y Bienestar Social; 2019.

Reiberger T, Lens S, Cabibbo G, et al. EASL position paper on clinical follow-up after HCV cure. J Hepatol 2024;81:326-44.
DOI: 10.1016/j.jhep.2024.04.007

Rodríguez-Tajes S, Pocurull A, Castillo J, et al. Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025. J Hepatol 2020;73:1360-7.
DOI: 10.1016/j.jhep.2020.07.018

Morgan RL, Baack B, Smith BD, et al. Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma: A Meta-analysis of Observational Studies. Ann Intern Med 2013;158:329-37.
DOI: 10.7326/0003-4819-158-5-201303050-00005

Lockart I, Yeo MGH, Hajarizadeh B, et al. HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis. Hepatology 2022;76:139-54.
DOI: 10.1002/hep.32341

Akhtar E, Manne V, Saab S. Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis. Liver International 2015;35:30-6.
DOI: 10.1111/liv.12576

Singal AG, Rich NE, Mehta N, et al. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated with Increased Survival in Patients with a History of Hepatocellular Carcinoma. Gastroenterology 2019;157:1253-63.
DOI: 10.1053/j.gastro.2019.07.040

Mettke F, Schlevogt B, Deterding K, et al. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. Aliment Pharmacol Ther 2018;47:516-25.
DOI: 10.1111/apt.14427

Calvaruso V, Cabibbo G, Cacciola I, et al. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Gastroenterology 2018;155:411-21.e4.

Alavi M, Janjua NZ, Chong M, et al. Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study. J Viral Hepat 2018;25:473-81.
DOI: 10.1111/jvh.12837

Sanduzzi Zamparelli M, Lens S, Sapena V, et al. Incidence of hepatocellular carcinoma after hepatitis C cure with DAA in a cohort of patients with advanced liver disease. Results from a prospective screening program. J Hepatol 2019;70:e845.
DOI: 10.1016/S0618-8278(19)31689-5

Mariño Z, Darnell A, Lens S, et al. Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. J Hepatol 2019;70:874-84.
DOI: 10.1016/j.jhep.2019.01.005

Ganne-Carrié N, Nahon P. Hepatocellular carcinoma in the setting of alcohol-related liver disease. J Hepatol 2019;70:284-93.
DOI: 10.1016/j.jhep.2018.10.008

Rodríguez de Lope C, Reig M, Matilla A, et al. Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers. Med Clin (Barc) 2017;149:61-71.
DOI: 10.1016/j.medcli.2016.12.048

Turati F, Galeone C, Rota M, et al. Alcohol and liver cancer: a systematic review and meta-analysis of prospective studies. Ann Oncol 2014;25:1526-35.
DOI: 10.1093/annonc/mdu020

Heckley GA, Jarl J, Asamoah BO, G-Gerdtham U. How the risk of liver cancer changes after alcohol cessation: a review and meta-analysis of the current literature. BMC Cancer 2011;11:446.
DOI: 10.1186/1471-2407-11-446

Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023;79:1542-56.
DOI: 10.1016/j.jhep.2023.06.003

Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2022;7:851-61.
DOI: 10.1016/S2468-1253(22)00165-0

Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatol 2018;67:123-33.
DOI: 10.1002/hep.29466

Anstee QM, Reeves HL, Kotsiliti E, et al. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol 2019;16:411-28.
DOI: 10.1038/s41575-019-0145-7

Alexander M, Loomis AK, Van Der Lei J, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: Real-world study of 18 million patients in four European cohorts. BMC Med 2019;17:95.
DOI: 10.1186/s12916-019-1321-x

Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology 2016;63:827-38.
DOI: 10.1002/hep.28368

Orci LA, Sanduzzi-Zamparelli M, Caballol B, et al. Incidence of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression. Clin Gastroenterol Hepatol 2022;20:283-92.
DOI: 10.1016/j.cgh.2021.05.002

Sangro B, Argemi J, Ronot M, et al. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol 2025;82:315-74.
DOI: 10.1016/j.jhep.2024.08.028

Cao W, Yu P, Yang KP, et al. Aflatoxin B1: metabolism, toxicology, and its involvement in oxidative stress and cancer development. Toxicol Mech Methods 2022;32:395-419.
DOI: 10.1080/15376516.2021.2021339

Jin J, Kouznetsova VL, Kesari S, et al. Synergism in actions of VHB with aflatoxin in cancer development. Toxicology 2023;499.
DOI: 10.1016/j.tox.2023.153652

Kensler TW, Egner PA, Wang JB, et al. Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterology 2004;127:S310-8.
DOI: 10.1053/j.gastro.2004.09.046

Lee YCA, Cohet C, Yang YC, et al. Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer. Int J Epidemiol 2009;38:1497-511.
DOI: 10.1093/ije/dyp280

Kanwal F, Khaderi S, Singal AG, et al. Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology 2023;77:997-1005.
DOI: 10.1002/hep.32434

Wu X, Zhang X, Yu X, et al. Exploring the association between air pollution and the incidence of liver cancers. Ecotoxicol Environ Saf 2025;290.
DOI: 10.1016/j.ecoenv.2024.117437

Wu HC, Wang Q, Wang LW, et al. Polycyclic aromatic hydrocarbon- and aflatoxin-albumin adducts, hepatitis B virus infection and hepatocellular carcinoma in Taiwan. Cancer Lett 2007;252:104-14.
DOI: 10.1016/j.canlet.2006.12.010

Torrens L, Puigvehí M, Torres-Martín M, et al. Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents. Clinical Cancer Research 2022;28:4509-20.
DOI: 10.1158/1078-0432.CCR-22-0632

Stevenson ED, Kleinman MT, Bai X, et al. Critical review on PFOA, kidney cancer, and testicular cancer. J Air Waste Manage Assoc 2021;71:1265-76.
DOI: 10.1080/10962247.2021.1975995

Goodrich JA, Walker D, Lin X, et al. Exposure to perfluoroalkyl substances and risk of hepatocellular carcinoma in a multiethnic cohort. JHEP Reports 2022;4.
DOI: 10.1016/j.jhepr.2022.100550

Bravi F, Bosetti C, Tavani A, et al. Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol 2013;11:1413-21.e1.
DOI: 10.1016/j.cgh.2013.04.039

Yu J, Liang D, Li J, et al. Coffee, Green Tea Intake, and the Risk of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Observational Studies. Nutr Cancer 2023;75:1295-308.
DOI: 10.1080/01635581.2023.2178949

Zhang J, Fu S, Liu D, et al. Statin can reduce the risk of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2023;35:353-8.
DOI: 10.1097/MEG.0000000000002517

Choi J, Nguyen VH, Przybyszewski E, et al. Statin Use and Risk of Hepatocellular Carcinoma and Liver Fibrosis in Chronic Liver Disease. JAMA Intern Med 2025.
DOI: 10.1001/jamainternmed.2025.0115

Simon TG, Duberg A-S, Aleman S, et al. Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. New Engl J Med 2020;382:1018-28.
DOI: 10.1056/NEJMoa1912035

Kraglund F, Christensen DH, Eiset AH, et al. Effects of statins and aspirin on HCC risk in alcohol-related cirrhosis: Nationwide emulated trials. Hepatol Commun 2023;7.
DOI: 10.1097/HC9.0000000000000013

Zeng RW, Yong JN, Tan DJH, et al. Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin. Aliment Pharmacol Ther 2023;57:600-9.
DOI: 10.1111/apt.17371

Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med 2025.
DOI: 10.1056/NEJMoa2413258

Wang L, Berger NA, Kaelber DC, et al. Association of GLP-1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients with Type 2 Diabetes. Gastroenterology 2024;167:689-703.
DOI: 10.1053/j.gastro.2024.04.029

Revisión: Epidemiología del cáncer de esófago

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF